bearish
Jinxin Fertility Co Ltd (1951.HK) - Hard to Achieve Performance Reversal in 2023
692 Views29 Dec 2022 08:55
The growth ceiling in China is obvious, which cannot support Jinxin’s valuation expansion.The breakthrough point is internationalization, but Jinxin’s 2023 performance is hard to have expected rebound
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- Modern Dental Group (3600.HK)- 2023 Harsh Reality Is Hard to Avoid, but Short-Term Rally Is Possible10 Jan 2023
- China Healthcare Weekly (Jan.6) - Dental Implant VBP, “Long COVID” Effect, 2023 Is Better than 202208 Jan 2023
- China Healthcare Weekly (Jan.1) - NRDL Negotiation Turnaround, Pullback of TCM, Biotech Sales System02 Jan 2023
- Jinxin Fertility Co Ltd (1951.HK) - Hard to Achieve Performance Reversal in 202329 Dec 2022
- Interpretation of China’s Central Economic Work Conference for 202320 Dec 2022
- China Makes U-Turn on COVID Policy - Here Are the Direct Impacts and Investment Opportunities19 Dec 2022
- Jinxin Fertility Co Ltd (1951.HK) - The Outlook Is Not Optimistic Even with Policy Support14 Apr 2022
x